Kisspeptin-10

Name: Kisspeptin-10
Brand: LyoPep

Amidated KISS1(45–54) decapeptide · KISS1R/GPR54 research agonist

≥ 99.0% · target, verify batch COACAS 374675-21-5RUO

Batch COA

MOQ1 kit (10 vials) per SKU

Supplied formDecapeptide (linear)

Lead time10–18 days

Kisspeptin-10 — Lyophilized material; confirm released-lot appearance on the COA

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value includes KISS1R/GPR54 signaling, GnRH/LH pulse physiology, reproductive-axis pharmacodynamics, isoform PK comparisons, receptor desensitization, peptide aggregation and formulation research
IVF live-birth, OHSS, HSDD and intranasal outcomes from Kisspeptin-54 must not be marketed as KP-10 benefits.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 374675-21-5
Formula: C₆₃H₈₃N₁₇O₁₄
Molecular weight: 1302.46 g/mol
Appearance: Lyophilized material; confirm released-lot appearance on the COA
Purity: ≥ 99.0% · target, verify batch COA
Storage: Use the released lot's COA and formulation-specific stability instructions. Control light, temperature, moisture, adsorption, aggregation, matrix, concentration, container and freeze-thaw exposure. Rat decomposition data and vendor guidance do not establish a universal reconstituted shelf life.
MOQ: 1 kit (10 vials) per SKU
Lead time: 10–18 days

PubChem CID 25240297

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about Kisspeptin-10

Kisspeptin-10 is the amidated 10-residue C-terminal active sequence of KISS1-derived kisspeptins and an agonist of KISS1R/GPR54. Genetics establishes the pathway's central role in puberty and reproductive endocrine signaling, and a small intravenous study in healthy men demonstrated KP-10-induced LH responses. Most widely cited IVF, hypothalamic-amenorrhea, HSDD and intranasal studies used Kisspeptin-54, not KP-10. FDA found insufficient evidence to conclude that KP-10 is effective for secondary hypogonadism in men.

Appropriate research contexts include reproductive neuroendocrine signaling, controlled human PD studies, KISS1R pharmacology, puberty/hypogonadism genetics, isoform comparison, desensitization and formulation/aggregation studies
Evidence from Kisspeptin-54 IVF, amenorrhea, psychosexual and intranasal programs is class context, not direct KP-10 efficacy.

Mechanism context

The question the literature is testing

KP-10 activates KISS1R/GPR54 within the reproductive neuroendocrine axis and can stimulate GnRH-dependent gonadotropin secretion. Response magnitude and desensitization depend on isoform, exposure pattern, dose, sex and physiological state. A short circulating half-life does not justify a weekly schedule, and pathway biology does not validate TRT, fertility-preservation or post-cycle protocols.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaHormonal research

Routes reported in sources

SubcutaneousIntravenousIntramuscularIntranasal

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Research-use-only material; not for human or veterinary administration
FDA identified inadequate characterization, insufficient effectiveness evidence for secondary hypogonadism, limited route-specific safety information and potential immunogenicity amplified by aggregation or peptide-related impurities
FDA proposed not including Kisspeptin-10 on the 503A Bulks List, and PCAC voted 0–11 against inclusion because convincing safety and efficacy data were lacking; the advisory vote is non-binding
This lot is not an approved fertility, HSDD or hormone therapy product.

Interactions reported in the literature

No validated retail interaction or compatibility table exists
Do not infer safe synergy with GnRH, hCG, testosterone, estrogen, fertility protocols or anabolic-steroid post-cycle therapy
Experimental co-exposure requires endocrine monitoring, prespecified controls and institutional review.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

Kisspeptin-10 batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

5 mg
10 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

Require complete sequence and C-terminal amidation, intact mass, peptide content, related-peptide and aggregate profiles, counterion, water and residual solvents, plus light- and formulation-specific stability
Add validated endotoxin, bioburden or sterility controls only when the research model requires them
White powder or a clear solution alone does not establish identity or suitability.

Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

KS55 mg10 vials

KS1010 mg10 vials

Other format

Also available as a nasal spray (US stock)

Black 10 mL nasal spray bottle with a clear cap — 10 mL nasal spray bottle

Besides lyophilized vials, Kisspeptin-10 is also supplied as a nasal spray solution, shipped from our US stock.

Strengths: 10 mg
Bottle sizes: 10 mL or 20 mL
Minimum order: 10 bottles per strength and bottle size
Ships from: Our US stock

Handling

Plan storage before the parcel arrives

Use the released lot's COA and formulation-specific stability instructions. Control light, temperature, moisture, adsorption, aggregation, matrix, concentration, container and freeze-thaw exposure. Rat decomposition data and vendor guidance do not establish a universal reconstituted shelf life.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Direct KP-10 evidence: George et al. 2011 (PMID 21632807), small healthy-male intravenous PD study; KP-10/KP-54 persistence comparison (PMID 28464043); and rat analytical/stability work (PMID 23524040). Pathway genetics: Seminara et al. and de Roux et al. 2003. Kisspeptin-54 studies in amenorrhea, IVF, HSDD and intranasal delivery are retained only with explicit isoform separation. FDA compounding-review materials, the proposal not to include Kisspeptin-10 on the 503A Bulks List and the non-binding 0–11 PCAC vote control current risk and effectiveness wording.

01
The GPR54 gene as a regulator of puberty
New England Journal of Medicine · 2003 · peer-reviewed original research (landmark human/mouse genetics)
Open source
02
Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54
Proceedings of the National Academy of Sciences U.S.A. · 2003 · peer-reviewed original research (landmark human genetics)
Open source
03
Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
The Journal of Clinical Endocrinology & Metabolism · 2011 · peer-reviewed original research (human pharmacodynamic study)
Open source
04
Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using Intravenous Infusion of Kisspeptin-54
The Journal of Clinical Endocrinology & Metabolism · 2014 · peer-reviewed original research (human clinical pharmacology, placebo-controlled)
Open source
05
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization
Journal of Clinical Investigation · 2014 · peer-reviewed original research (human clinical trial)
Open source
06
Kisspeptin modulates sexual and emotional brain processing in humans
Journal of Clinical Investigation · 2017 · peer-reviewed original research (randomized, double-blind, human fMRI study)
Open source
07
Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
JAMA Network Open · 2023 · peer-reviewed original research (randomized, double-blind, placebo-controlled crossover clinical trial)
Open source
08
Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
JAMA Network Open · 2022 · peer-reviewed original research (randomized, double-masked, placebo-controlled crossover clinical trial)
Open source

Product FAQ

Questions buyers ask about Kisspeptin-10

How does Kisspeptin-10 differ from Kisspeptin-54 and other KISS1 fragments?+

Kisspeptin-54, -14, -13 and -10 share the amidated C-terminal RF-amide sequence that activates KISS1R/GPR54, but they are different analytes with different length, stability and pharmacokinetic behavior. KP-10 is YNWNSFGLRF-NH₂; a KP-54 IVF, amenorrhea, HSDD or intranasal result cannot be relabeled as KP-10 evidence. An order and study report must identify the exact isoform, termini, salt, formulation and exposure protocol.

Which identity and quality attributes are critical for a Kisspeptin-10 lot?+

Specify H-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂, C-terminal amidation, stereochemistry and counterion. Require high-resolution intact mass, sequence-confirming identity, quantitative peptide content, related-peptide and aggregate profiles, water and residual solvents, plus light- and formulation-specific stability. A white powder, clear solution, CAS or HPLC area purity alone cannot distinguish KP-10 from another kisspeptin fragment or establish usable concentration.

Evidence before order

Buyer intelligence

Ready for review

Request a usable quote

Include fill, quantity, target purity/content, required methods, destination and timing.

B2B response target: 24 hours
1 kit MOQ per SKU
Batch COA: HPLC, MS, endotoxin, fill

Research Use Only. Human-use requests are not accepted.

Recent activity window

Recent confirmed orders including Kisspeptin-10

Recent Confirmed Orders2 · Last 30 days

United Kingdom570 mg2026-10-24

GHK-Cu 50 mg · Kisspeptin-10 5 mg · Semaglutide 2 mg

Australia23 g2026-10-22

Retatrutide 60 mg · Sermorelin 10 mg · Hexarelin Acetate 5 mg · Semaglutide 50 mg · Tesa+IP5 15 mg · BPC-157 10 mg · Melanotan II 10 mg · Kisspeptin-10 10 mg · TB500 Fragment (Frag 17-23) 10 mg · CJC-1295 without DAC 10 mg · MOTS-c (Human) 40 mg

Only a portion of all confirmed orders is shown here.

Kisspeptin-10

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Kisspeptin-10

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Kisspeptin-10 batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Also available as a nasal spray (US stock)

Plan storage before the parcel arrives

Terms to settle before the purchase order

Literature behind the research context

The GPR54 gene as a regulator of puberty

Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54

Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men

Increasing LH Pulsatility in Women With Hypothalamic Amenorrhoea Using Intravenous Infusion of Kisspeptin-54

Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization

Kisspeptin modulates sexual and emotional brain processing in humans

Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial

Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial

Questions buyers ask about Kisspeptin-10

Buyer intelligence

Compare adjacent molecules and documentation needs.

Oxytocin Acetate

ACTH 1-39

HMG

Gonadorelin Acetate